Skip to content
2000
Volume 20, Issue 11
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.

Loading

Article metrics loading...

/content/journals/ppl/10.2174/09298665113209990067
2013-11-01
2025-12-14
Loading full text...

Full text loading...

/content/journals/ppl/10.2174/09298665113209990067
Loading

  • Article Type:
    Research Article
Keyword(s): Amylin; diabetes; glycemia; islet associated polypeptide; PEGylation
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test